Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CBLC
REST API REST API
Homo sapiens
CBLC is differentially expressed in 156 experiments: 114 organism parts: esophagus, lung, ... (112 more);, 145 disease states: normal, adenocarcinoma, ... (143 more);, 48 cell types 466 cell lines 15 compound treatments and 56 other conditions.
Synonyms RNF57, CBL-3, CBL-SL
Orthologs ENSCING00000002655 (Ciona intestinalis)   Cblc (Rattus norvegicus)   CBLC (Danio rerio)   A6QPZ5_BOVIN (Bos taurus)   Cblc (Mus musculus)   Cbl (Drosophila melanogaster)   CBLC (Canis familiaris)   (Compare orthologs)
Gene Ontology Term negative regulation of epidermal growth factor receptor signaling pathway, protein binding, SH3 domain binding, epidermal growth factor receptor binding, protein ubiquitination involved in ubiquitin-dependent protein catabolic process, signal transducer activity, cell surface receptor linked signaling pathway, nucleus, ubiquitin-protein ligase activity, negative regulation of MAP kinase activity, calcium ion binding, zinc ion binding, phosphotyrosine binding, regulation of signaling, negative regulation of epidermal growth factor-activated receptor activity
InterPro Term Znf_RING, Znf_C3HC4_RING-type, Adaptor_Cbl_SH2-like, Adaptor_Cbl_EF_hand-like, Adaptor_Cbl_N_hlx
UniProt Accession Q9ULV8
Search EB-eye ENSG00000142273
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-7224, E-MTAB-24, E-MTAB-25, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (29 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-5823, E-GEOD-20081, E-GEOD-3529
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
primary culture
2
E-GEOD-2450, E-GEOD-1657
AGS
2
E-MTAB-37, E-GEOD-15460
BT20
2
E-MTAB-37, E-MTAB-62
460 more value(s).


Cell type

studied in E-GEOD-22373, E-MEXP-2426, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, ... (33 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18147, E-GEOD-18265
stromal cell
2
E-MEXP-2034, E-GEOD-1460
embryonic stem cell
1
2
E-MEXP-930, E-MEXP-2426, E-GEOD-2248
secretory cell
1
E-GEOD-3998
white blood cell
1
E-GEOD-2006
osteoblast
1
E-MEXP-1216
42 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-1869, E-MEXP-2069, E-GEOD-2549, ... (34 experiments)

Factor Value U/D Experiments
prostate carcinoma
2
E-GEOD-7307, E-MEXP-2034
colon carcinoma
2
E-MTAB-37, E-GEOD-3726
gastric carcinoma
2
E-MTAB-37, E-GEOD-15460
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
Huntington's disease
1
E-GEOD-1751
non-ischemic cardiomyopathy
1
E-GEOD-1869
139 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-20719, E-GEOD-5258, E-GEOD-3284, E-GEOD-6907, ... (11 experiments)

Factor Value U/D Experiments
glucose
1
E-MEXP-941
placebo
1
E-MEXP-1335
Cxcl12
1
E-GEOD-7307
bacterial endotoxin
1
1
E-GEOD-3284
dimethyl sulfoxide
1
E-GEOD-5824
rapamycin
1
E-GEOD-5824
9 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

Developmental stage
studied in E-GEOD-20033

Disease staging
studied in E-GEOD-19743, E-GEOD-3325

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023

Genotype
studied in E-GEOD-22056, E-GEOD-17347

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-22278

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-MEXP-2069, E-GEOD-6919, E-GEOD-16363, E-MEXP-935, ... (13 experiments)

Infection
studied in E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1657

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-101

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.403 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM